ProShares Ultra NASDAQ Biotechnology
32 hedge funds and large institutions have $26.1M invested in ProShares Ultra NASDAQ Biotechnology in 2017 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 11 increasing their positions, 7 reducing their positions, and 4 closing their positions.
100% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 4
57% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 7
14% more funds holding
Funds holding: 28 → 32 (+4)
10% more capital invested
Capital invested by funds: $23.7M → $26.1M (+$2.4M)
0.73% more ownership
Funds ownership: 6.11% → 6.84% (+0.73%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
9% less call options, than puts
Call options by funds: $16.6M | Put options by funds: $18.3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OPPM
Opus Point Partners Management
New York
|
+$2.22M |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$941K |
| 3 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$927K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$712K |
| 5 |
VKH
Virtu KCG Holdings
New York
|
+$443K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MIAN
Mariner Independent Advisor Network
Overland Park,
Kansas
|
-$4.05M |
| 2 |
PCA
Private Capital Advisors
Darien,
Connecticut
|
-$994K |
| 3 |
TH
Timber Hill
Greenwich,
Connecticut
|
-$721K |
| 4 |
BA
BKS Advisors
Southfield,
Michigan
|
-$429K |
| 5 |
Walleye Trading
New York
|
-$167K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LTFS
26
Ladenburg Thalmann Financial Services
Miami,
Florida
| $13K | +$3.76K | +77 | +43% |
|
|
GWM
27
Geneos Wealth Management
Englewood,
Colorado
| $9K | – | – | – |
|
|
AG
28
Advisor Group
Phoenix,
Arizona
| $6K | +$5.37K | +110 | New |
|
|
CG
29
Cutler Group
San Francisco,
California
| $5K | – | – | – |
|
30
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| $5K | +$4.88K | +100 | New |
|
|
31
Walleye Trading
New York
| $7 | -$167K | -3,417 | -97% |
|
|
MIAN
32
Mariner Independent Advisor Network
Overland Park,
Kansas
| – | -$4.05M | -83,962 | Closed |
|
|
TH
33
Timber Hill
Greenwich,
Connecticut
| – | -$721K | -14,938 | Closed |
|
|
BGC
34
Blue Granite Capital
Charleston,
South Carolina
| – | -$145K | -3,000 | Closed |
|
35
UBS Group
Zurich,
Switzerland
| – | -$6K | -121 | Closed |
|
BIB Hedge Fund Activity: Q2 2017 in Review
32 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in ProShares Ultra NASDAQ Biotechnology (BIB) for Q2 2017, worth a combined $26.1M — up 10% from $23.7M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new BIB positions and 4 closed out — a net gain of 4 holders — while 11 added to existing stakes and 7 trimmed.
The largest buyer was Opus Point Partners Management, adding an estimated $2.22M. The largest seller was Mariner Independent Advisor Network, exiting entirely with an estimated $4.05M sold.
- 32 institutional investors held ProShares Ultra NASDAQ Biotechnology (BIB) as of Q2 2017, up from 28 in Q1 2017.
- Funds reported $26.1M of ProShares Ultra NASDAQ Biotechnology stock for Q2 2017, up 10% quarter-over-quarter.
- 8 funds opened new ProShares Ultra NASDAQ Biotechnology positions in Q2 2017 and 4 closed out, a net change of +4 holders.
- The largest ProShares Ultra NASDAQ Biotechnology buyer in Q2 2017 was Opus Point Partners Management, an estimated $2.22M added.
- The largest ProShares Ultra NASDAQ Biotechnology seller in Q2 2017 was Mariner Independent Advisor Network, an estimated $4.05M sold.
Based on aggregated 13F filings for Q2 2017.